Autolus Therapeutics(DE:6A3A)
€1.100.00 (0.00%)
DE:6A3A
Autolus Therapeutics earnings date
€1.10
At close:0.00 (0.00%)
Autolus Therapeutics (6A3A) Q3 2026 Earnings Report
3 Followers
DE:6A3A Q3 2026 EPS Results
- Actual EPS
- -EUR 0.19
- Consensus EPS
- -EUR 0.15
- Beat/Miss
- Missed by -EUR 0.04
- One Year Ago EPS
- -EUR 0.27
DE:6A3A Q3 2026 Revenue Results
- Actual Revenue
- EUR 36.90M
- Expected Revenue
- EUR 35.40M
- Beat/Miss
- Beat by +EUR 1.51M
- YoY Revenue Growth
- +95.70%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/10/2026
- Time
- Before Open
- Conference Call
- Tuesday, November 10, 2026
DE:6A3A Upcoming Earnings
Autolus Therapeutics's next earnings date is estimated for March 10, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
DE:6A3A Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was strongly positive overall, driven by 95% year-over-year quarterly revenue growth, 122% year-to-date sales growth, guidance of at least $150 million for 2026, a 57% gross margin, faster-than-planned center activation, improved losses, and a cash runway into the second quarter of 2028. The main challenges were continuing operating losses, higher R&D spending, seasonal fourth-quarter effects, expected moderation in later-year sales growth, and the decision to delay BOBCAT data presentation to obtain longer follow-up.
Company Guidance
Autolus expects full year 2026 AUCATZYL net revenue for the U.S. and U.K. combined to be “at or above $150 million,” with gross margin at 44% for the first 9 months and 57% in Q3, and expects to approach the “upper end of the range” of 65% to 70% in 2028; current and projected cash, cash equivalents and marketable securities are expected to fund operations “into the second quarter of 2028,” assuming $25 million from the second tranche and combined first and second tranches of $100 million. CATULUS is on track to complete enrollment “end of 2026 or early 2027,” and BOBCAT data are planned for ECTRIMS in October 2027, with 12 patients having at least 12 months of follow-up and 12 additional patients having 6 to 12 months of follow-up.
- Strong AUCATZYL Revenue GrowthThird-quarter AUCATZYL net revenue was $41.2 million, up 95% from $21.1 million in Q3 2025. First-nine-month net sales were $113.1 million, up 122% compared with the first nine months of 2025.
- Full-Year Revenue Outlook Raised Above $150 MillionFull-year 2026 AUCATZYL net revenue guidance progressed from $120 million to $135 million, to $140 million to $150 million, and is now expected to be at or above $150 million for the combined U.S. and U.K. business.
- Expansion of Authorized Treatment CentersCenter onboarding is progressing ahead of plan, with 90 authorized centers in the U.S. and 18 in the U.K. The company achieved its 2026 goal of activating 80 U.S. centers in Q3 and added 10 more centers, creating a strong base for Q4.
- U.K. Launch Progressing WellThe U.K. launch was described as going well, with U.K. sales expected to be reported separately with the full-year financial results.
- Gross Margin TurnaroundGross margin reached 57% in Q3 2026, compared with 55% in Q2 2026 and a negative gross margin in Q3 2025. Gross margin was 44% for the first nine months of 2026.
- Manufacturing Efficiency ImprovementsThe company attributed gross-margin improvement to increased production volumes, lower manufacturing cost per batch, ongoing operational efficiency initiatives, and lower inventory reserves and write-offs versus the prior-year quarter. In 2026, the company expects to manufacture more than double the number of products made in 2025 with staffing below 2025 levels.
- Lower Cost of SalesQ3 cost of sales decreased to $17.9 million from $28.6 million in Q3 2025, reflecting the manufacturing and inventory-related improvements discussed on the call.
- Path Toward Higher Gross MarginsThe company expects gross-margin improvement to continue through ongoing manufacturing efficiencies, describing the expected progression as continuous improvement rather than a step change. Management said it expects to approach the upper end of its indicated 65% to 70% range for the ALL business alone in 2028.
- Improved Operating and Net LossesQ3 loss from operations improved to $43.5 million from $71.6 million in Q3 2025. Net loss improved to $55.1 million from $79.1 million in the prior-year quarter.
- Extended Cash RunwayCash, cash equivalents, and marketable securities totaled $248.4 million at September 30, 2026, compared with $201.6 million at the end of June. The increase was primarily driven by the initial $75 million tranche of the Perceptive Advisors credit facility. Including the available second $25 million tranche, the company expects its current and projected liquidity to fund operations into the second quarter of 2028.
- Positive Physician Experience and Real-World EvidenceManagement said AUCATZYL performance was supported by positive treating-physician experience and consistently strong execution by the commercial teams. Additional real-world AUCATZYL data from the ROCCA consortium are expected at ASH, with management stating that peer-to-peer physician communication has had a significant impact and is expected to continue supporting adoption.
- Promising CARLYSLE SLE Follow-UpThe company presented longer-term follow-up from the Phase I CARLYSLE study in severe refractory SLE patients, showing sustained clinical responses and a safety profile with up to 25 months of follow-up.
- Additional Clinical Data ExpectedThe company expects additional AUCATZYL data in adult relapsed/refractory ALL from clinical-trial and real-world experiences at ASH, first data for AUTO8 in light-chain amyloidosis, and continued enrollment in CATULUS for pediatric ALL and LUMINA for refractory lupus nephritis.
- BOBCAT Study Remains on TrackBOBCAT enrollment is on track with no study delay. The company plans to present data at ECTRIMS in October 2027, when it expects to have 12 patients with at least 12 months of follow-up and 12 additional patients with 6 to 12 months of follow-up.
- Encouraging SLE Pharmacokinetic and Safety ObservationsThe company reported good cell expansion in all SLE patients, typical product persistence of about 3 months, and subsequent B-cell compartment reconstitution. Management said the 50 million cell dose was highly active and performed extremely well, while also stating that it could not conclude that the observed fluctuations reflected a dose-level difference.
- Clinical-Trial Recruitment Remains ResilientManagement said it had not observed a meaningful recruitment impact in the second half of the year from broader CAR-T safety concerns. Recruitment in progressive MS was described as robust, and the company said patient flow had not visibly changed across its autoimmune clinical trials.
- Targeted Center Expansion StrategyManagement said approximately 80 U.S. centers provide access to roughly 80% of patients. Future expansion is being targeted around reducing patient travel distances, following physicians who move to new centers, and identifying nonacademic centers with stronger-than-expected ALL patient flows.
DE:6A3A Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 10, 2027 | 2026 (Q4) | -0.15- | -0.3 | ― | ― |
| Nov 10, 2026 | 2026 (Q3) | -0.15-0.19 | -0.27 | 30.00% (+0.08) | |
| Aug 11, 2026 | 2026 (Q2) | -0.17-0.13 | -0.16 | 16.67% (+0.03) | |
| May 14, 2026 | 2026 (Q1) | -0.23-0.24 | -0.23 | -3.85% (-0.01) | |
| Mar 27, 2026 | 2025 (Q4) | -0.23-0.30 | -0.08 | -277.78% (-0.22) | |
| Nov 12, 2025 | 2025 (Q3) | -0.19-0.27 | -0.28 | 3.23% (+0.01) | |
| Aug 12, 2025 | 2025 (Q2) | -0.21-0.16 | -0.2 | 18.18% (+0.04) | |
| May 08, 2025 | 2025 (Q1) | -0.22-0.23 | -0.21 | -8.33% (-0.02) | |
| Mar 20, 2025 | 2024 (Q4) | -0.18-0.08 | -0.39 | 79.55% (+0.31) | |
| Nov 12, 2024 | 2024 (Q3) | -0.19-0.28 | -0.23 | -19.23% (-0.04) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
